IL17A and respiratory system disorder: So, as COVID-19 is also a respiratory disease, the production of IL-17A in the upper airway of individuals with SARS-Cov-2 infection can be crucial to elicit an immune response that limits disease severity (36), particularly by inducing specific-SIgA for COVID-19 as observed in the present study.